# Data Changes for the CCDD MAY Release Candidate 2020

## Based on the QA Release 20200508

|  |  |
| --- | --- |
| Data entered by | Jo-Anne Hutsul |
| Data checked by | Barbara Jovaisas |

## TM File

### Deprecation

The following concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### Code permanence – name changes

The following concept(s) need to keep their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### Concept permanence - returns

In addition, the following concept is “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## NTP File

### Deprecation

The following concept(s) need to be added back into the NTP File with status of **deprecated**. In one, the ntp\_formal\_name is longer being used since the active ingredient in DPD changed from chloroquine diphosphate to chloroquine phosphate. In the other, the dosage form in DPD changed from solution to syrup with the former ntp no longer in use.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9001632 | chloroquine diphosphate 250 mg oral tablet | diphosphate de chloroquine 250 mg comprimé oral | Deprec |
| 9013783 | dextromethorphan hydrobromide 10 mg per 5 mL and guaifenesin 100 mg per 5 mL oral solution | bromhydrate de dextrométhorphane 10 mg par 5 mL et guaïfénésine 100 mg par 5 mL solution orale | Deprec |

### Manual correction for May release

The following concept will need a manual override for this month to correct the case from upper to lower in the ntp\_fr\_description. This should also apply to the FR Relationship file. The correction will be made in the ing stem file once the release is complete.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description-incorrect case** | **ntp\_fr\_description – use this concept** |
| 9bd9344652c0b85e80c72a86cd56ba80 | chloroquine phosphate 250 mg oral tablet | Phosphate de chloroquine 250 mg comprimé oral | phosphate de chloroquine 250 mg comprimé oral |

### Code permanence – name changes

The following concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### Concept permanence – returns check

The following four concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist” as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
|  | [NONE] |

## MP File

### Deprecation (very rare)

**No new deprecated concepts**

### Deprecation – manual return

The following concepts need to be added back into the MP File with status of **deprecated**. For both DINs, they have had additional UoP added. Both products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |

The following concepts are generating as active but need to be set to **deprecated**. For both products, they have been assigned a new DIN (02474891, 02474735). This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |

### DPD descriptors

The following concepts needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |
|  |  |  |  |  |

### Manual correction for May release

The following concept will need a manual override for this month to correct the case from upper to lower in the mp\_fr\_description. This should also apply to the FR Relationship file. The correction will be made in the ing stem file once the release is complete.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp\_formal\_name** | **mp\_fr\_description - incorrect** | **mp\_fr\_description – use this concept** |
| 9bd9344652c0b85e80c72a86cd56ba80 | chloroquine phosphate 250 mg oral tablet | Phosphate de chloroquine 250 mg comprimé oral | phosphate de chloroquine 250 mg comprimé oral |

### Concept permanence – manual return

One concept needs to be added back into the generation with its status as **active**. For this product, in the DPD it has gone back to Approved while the company “reactivates” its DIN. In addition, two products (AUVI-Q) need to be added back into the generation with its status as **Inactive** as the interim order has expired and there is no longer product on the shelf**.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
| 15207 | 01916947 | BACTROBAN (mupirocin 2 % cutaneous ointment) GLAXOSMITHKLINE CONSUMER HEALTHCARE INC. | BACTROBAN (mupirocine 2 % pommade cutanée) GLAXOSMITHKLINE CONSUMER HEALTHCARE INC. | Active |
|  | 02480379 | AUVI-Q (epinephrine 0.3 mg per 0.3 mL solution for injection syringe) KALEO INC | AUVI-Q (épinéphrine 0,3 mg par 0,3 mL solution injectable seringue) KALEO INC | Inactive |
|  | 02480360 | AUVI-Q (epinephrine 0.15 mg per 0.15 mL solution for injection syringe) KALEO INC | AUVI-Q (épinéphrine 0,15 mg par 0,15 mL solution injectable seringue) KALEO INC | Inactive |

### Concept permanence – returns check

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | DPD status |
| As below | 77700648 | ACETYLCYSTEINE INJECTION (acetylcysteine 200 mg per mL solution for injection 10 mL vial) TELIGENT OU | ACETYLCYSTEINE INJECTION (acétylcystéine 200 mg par mL solution injectable 10 mL fiole) TELIGENT OU |
| 78573 | 77700649 | ACETYLCYSTEINE INJECTION (acetylcysteine 200 mg per mL solution for injection 30 mL vial) TELIGENT OU | ACETYLCYSTEINE INJECTION (acétylcystéine 200 mg par mL solution injectable 30 mL fiole) TELIGENT OU |
| 74138 | 02256150 | ACT GABAPENTIN (gabapentin 300 mg oral capsule) ACTAVIS PHARMA COMPANY | ACT GABAPENTIN (gabapentine 300 mg capsule orale) ACTAVIS PHARMA COMPANY |
| 74139 | 02256169 | ACT GABAPENTIN (gabapentin 400 mg oral capsule) ACTAVIS PHARMA COMPANY | ACT GABAPENTIN (gabapentine 400 mg capsule orale) ACTAVIS PHARMA COMPANY |
| 44263 | 02182963 | APO-METHOTREXATE (methotrexate 2.5 mg oral tablet) APOTEX INC | APO-METHOTREXATE (méthotrexate 2,5 mg comprimé oral) APOTEX INC |
| 94431 | 02457237 | APO-QUETIAPINE XR (quetiapine (quetiapine fumarate) 150 mg prolonged-release oral tablet) APOTEX INC | APO-QUETIAPINE XR (quétiapine (fumarate de quétiapine) 150 mg comprimé oral à libération prolongée) APOTEX INC |
| 94432 | 02457245 | APO-QUETIAPINE XR (quetiapine (quetiapine fumarate) 200 mg prolonged-release oral tablet) APOTEX INC | APO-QUETIAPINE XR (quétiapine (fumarate de quétiapine) 200 mg comprimé oral à libération prolongée) APOTEX INC |
| 94434 | 02457261 | APO-QUETIAPINE XR (quetiapine (quetiapine fumarate) 400 mg prolonged-release oral tablet) APOTEX INC | APO-QUETIAPINE XR (quétiapine (fumarate de quétiapine) 400 mg comprimé oral à libération prolongée) APOTEX INC |
| 94430 | 02457229 | APO-QUETIAPINE XR (quetiapine (quetiapine fumarate) 50 mg prolonged-release oral tablet) APOTEX INC | APO-QUETIAPINE XR (quétiapine (fumarate de quétiapine) 50 mg comprimé oral à libération prolongée) APOTEX INC |
| 3422 | 00436895 | BALMINIL DM (dextromethorphan hydrobromide 15 mg per 5 mL syrup) TEVA CANADA LIMITED | BALMINIL DM (bromhydrate de dextrométhorphane 15 mg par 5 mL sirop) TEVA CANADA LIMITED |
| 72878 | 02248525 | CLINDAMYCINE-150 (clindamycin (clindamycin hydrochloride) 150 mg oral capsule) PRO DOC LIMITEE | CLINDAMYCINE-150 (clindamycine (chlorhydrate de clindamycine) 150 mg capsule orale) PRO DOC LIMITEE |
| 77106 | 02285568 | COLGATE TOTAL - ADVANCED HEALTH (sodium fluoride 0.243 % and triclosan 0.3 % toothpaste) COLGATE-PALMOLIVE CANADA INC | COLGATE TOTAL - ADVANCED HEALTH (fluorure de sodium 0,243 % et triclosan 0,3 % pâte dentifrice) COLGATE-PALMOLIVE CANADA INC |
| 78525 | 02299909 | CUBICIN (daptomycin 500 mg per vial powder for solution for injection) CUBIST PHARMACEUTICALS LLC | CUBICIN (daptomycine 500 mg par fiole poudre pour solution injectable) CUBIST PHARMACEUTICALS LLC |
| 88436 | 02399482 | DOM-ATORVASTATIN (atorvastatin (atorvastatin calcium) 10 mg oral tablet) DOMINION PHARMACAL | DOM-ATORVASTATIN (atorvastatine (atorvastatine calcique) 10 mg comprimé oral) DOMINION PHARMACAL |
| 78470 | 02299313 | DOM-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 150 mg prolonged-release oral capsule) DOMINION PHARMACAL | DOM-VENLAFAXINE XR (venlafaxine (chlorhydrate de venlafaxine) 150 mg capsule orale à libération prolongée) DOMINION PHARMACAL |
| 78468 | 02299291 | DOM-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 37.5 mg prolonged-release oral capsule) DOMINION PHARMACAL | DOM-VENLAFAXINE XR (venlafaxine (chlorhydrate de venlafaxine) 37,5 mg capsule orale à libération prolongée) DOMINION PHARMACAL |
| 78469 | 02299305 | DOM-VENLAFAXINE XR (venlafaxine (venlafaxine hydrochloride) 75 mg prolonged-release oral capsule) DOMINION PHARMACAL | DOM-VENLAFAXINE XR (venlafaxine (chlorhydrate de venlafaxine) 75 mg capsule orale à libération prolongée) DOMINION PHARMACAL |
| 76151 | 02275856 | DURAGESIC (fentanyl 100 mcg per hour transdermal patch) JANSSEN INC | DURAGESIC (fentanyl 100 mcg par heure timbre transdermique) JANSSEN INC |
| 81986 | 02334186 | DURAGESIC (fentanyl 12 mcg per hour transdermal patch) JANSSEN INC | DURAGESIC (fentanyl 12 mcg par heure timbre transdermique) JANSSEN INC |
| 76148 | 02275813 | DURAGESIC (fentanyl 25 mcg per hour transdermal patch) JANSSEN INC | DURAGESIC (fentanyl 25 mcg par heure timbre transdermique) JANSSEN INC |
| 76149 | 02275821 | DURAGESIC (fentanyl 50 mcg per hour transdermal patch) JANSSEN INC | DURAGESIC (fentanyl 50 mcg par heure timbre transdermique) JANSSEN INC |
| 76150 | 02275848 | DURAGESIC (fentanyl 75 mcg per hour transdermal patch) JANSSEN INC | DURAGESIC (fentanyl 75 mcg par heure timbre transdermique) JANSSEN INC |
| 64100 | 02240530 | FLEXACRÈME EXTRA-STRENGTH (trolamine salicylate 15 % cutaneous cream) PHARMASCIENCE INC | FLEXACRÈME EXTRA-STRENGTH (salicylate de trolamine 15 % crème cutanée) PHARMASCIENCE INC |
| 76001 | 02274574 | GD-AZITHROMYCIN (azithromycin 200 mg per 5 mL oral suspension) GENMED A DIVISION OF PFIZER CANADA ULC | GD-AZITHROMYCIN (azithromycine 200 mg par 5 mL suspension orale) GENMED A DIVISION OF PFIZER CANADA ULC |
| 88494 | 02400111 | JAMP-ALPRAZOLAM (alprazolam 0.25 mg oral tablet) JAMP PHARMA CORPORATION | JAMP-ALPRAZOLAM (alprazolam 0,25 mg comprimé oral) JAMP PHARMA CORPORATION |
| 88495 | 02400138 | JAMP-ALPRAZOLAM (alprazolam 0.5 mg oral tablet) JAMP PHARMA CORPORATION | JAMP-ALPRAZOLAM (alprazolam 0,5 mg comprimé oral) JAMP PHARMA CORPORATION |
| 88496 | 02400146 | JAMP-ALPRAZOLAM (alprazolam 1 mg oral tablet) JAMP PHARMA CORPORATION | JAMP-ALPRAZOLAM (alprazolam 1 mg comprimé oral) JAMP PHARMA CORPORATION |
| 88497 | 02400154 | JAMP-ALPRAZOLAM (alprazolam 2 mg oral tablet) JAMP PHARMA CORPORATION | JAMP-ALPRAZOLAM (alprazolam 2 mg comprimé oral) JAMP PHARMA CORPORATION |
| 50000 | 02230737 | LOSEC 10 MG (omeprazole (omeprazole magnesium) 10 mg gastro-resistant tablet) ASTRAZENECA CANADA INC | LOSEC 10 MG (oméprazole (oméprazole magnésium) 10 mg comprimé gastrorésistant) ASTRAZENECA CANADA INC |
| 92763 | 02443090 | MINT-DORZOLAMIDE/TIMOLOL (dorzolamide (dorzolamide hydrochloride) 20 mg per mL and timolol (timolol maleate) 5 mg per mL ophthalmic drops) MINT PHARMACEUTICALS INC | MINT-DORZOLAMIDE/TIMOLOL (dorzolamide (chlorhydrate de dorzolamide) 20 mg par mL et timolol (maléate de timolol) 5 mg par mL gouttes ophtalmiques) MINT PHARMACEUTICALS INC |
| 90772 | 02422999 | MINT-IRBESARTAN (irbesartan 150 mg oral tablet) MINT PHARMACEUTICALS INC | MINT-IRBESARTAN (irbésartan 150 mg comprimé oral) MINT PHARMACEUTICALS INC |
| 87827 | 02393026 | MINT-IRBESARTAN/HCTZ (hydrochlorothiazide 25 mg and irbesartan 300 mg oral tablet) MINT PHARMACEUTICALS INC | MINT-IRBESARTAN/HCTZ (hydrochlorothiazide 25 mg et irbésartan 300 mg comprimé oral) MINT PHARMACEUTICALS INC |
| 87516 | 02389665 | MINT-LOSARTAN/HCTZ (hydrochlorothiazide 12.5 mg and losartan potassium 100 mg oral tablet) MINT PHARMACEUTICALS INC | MINT-LOSARTAN/HCTZ (hydrochlorothiazide 12,5 mg et losartan potassique 100 mg comprimé oral) MINT PHARMACEUTICALS INC |
| 86520 | 02379325 | MONTELUKAST (montelukast (montelukast sodium) 5 mg chewable tablet) SANIS HEALTH INC | MONTELUKAST (montélukast (montélukast sodique) 5 mg comprimé à croquer) SANIS HEALTH INC |
| 70782 | 02246595 | MYLAN-CITALOPRAM (citalopram (citalopram hydrobromide) 40 mg oral tablet) MYLAN PHARMACEUTICALS ULC | MYLAN-CITALOPRAM (citalopram (bromhydrate de citalopram) 40 mg comprimé oral) MYLAN PHARMACEUTICALS ULC |
| 93091 | 02445638 | OPTI-TEARS DRY EYE (hypromellose 3 mg per mL ophthalmic drops) ALCON CANADA INC | OPTI-TEARS DRY EYE (hypromellose 3 mg par mL gouttes ophtalmiques) ALCON CANADA INC |
| 81249 | 02327171 | OXYCODONE-ACET (acetaminophen 325 mg and oxycodone hydrochloride 5 mg oral tablet) PRO DOC LIMITEE | OXYCODONE-ACET (acétaminophène 325 mg et chlorhydrate d'oxycodone 5 mg comprimé oral) PRO DOC LIMITEE |
| 50885 | 02231542 | PMS-CARBAMAZEPINE (carbamazepine 100 mg chewable tablet) PHARMASCIENCE INC | PMS-CARBAMAZEPINE (carbamazépine 100 mg comprimé à croquer) PHARMASCIENCE INC |
| 71743 | 02247493 | PMS-FUROSEMIDE (furosemide 20 mg oral tablet) PHARMASCIENCE INC | PMS-FUROSEMIDE (furosémide 20 mg comprimé oral) PHARMASCIENCE INC |
| 77991 | 02294559 | PMS-PROPAFENONE (propafenone hydrochloride 150 mg oral tablet) PHARMASCIENCE INC | PMS-PROPAFENONE (chlorhydrate de propafénone 150 mg comprimé oral) PHARMASCIENCE INC |
| 77992 | 02294575 | PMS-PROPAFENONE (propafenone hydrochloride 300 mg oral tablet) PHARMASCIENCE INC | PMS-PROPAFENONE (chlorhydrate de propafénone 300 mg comprimé oral) PHARMASCIENCE INC |
| 84396 | 02358921 | PMS-RALOXIFENE (raloxifene hydrochloride 60 mg oral tablet) PHARMASCIENCE INC | PMS-RALOXIFENE (chlorhydrate de raloxifène 60 mg comprimé oral) PHARMASCIENCE INC |
| 81195 | 02326590 | PMS-ROPINIROLE (ropinirole (ropinirole hydrochloride) 0.25 mg oral tablet) PHARMASCIENCE INC | PMS-ROPINIROLE (ropinirole (chlorhydrate de ropinirole) 0,25 mg comprimé oral) PHARMASCIENCE INC |
| 81197 | 02326612 | PMS-ROPINIROLE (ropinirole (ropinirole hydrochloride) 1 mg oral tablet) PHARMASCIENCE INC | PMS-ROPINIROLE (ropinirole (chlorhydrate de ropinirole) 1 mg comprimé oral) PHARMASCIENCE INC |
| 81198 | 02326620 | PMS-ROPINIROLE (ropinirole (ropinirole hydrochloride) 2 mg oral tablet) PHARMASCIENCE INC | PMS-ROPINIROLE (ropinirole (chlorhydrate de ropinirole) 2 mg comprimé oral) PHARMASCIENCE INC |
| 90044 | 02415852 | RALOXIFENE (raloxifene hydrochloride 60 mg oral tablet) PRO DOC LIMITEE | RALOXIFENE (chlorhydrate de raloxifène 60 mg comprimé oral) PRO DOC LIMITEE |
| 33537 | 02222132 | REGULAR STRENGTH NO ODOUR CREAM (trolamine salicylate 13.3 % cutaneous cream) CHURCH & DWIGHT CANADA CORP | REGULAR STRENGTH NO ODOUR CREAM (salicylate de trolamine 13,3 % crème cutanée) CHURCH & DWIGHT CANADA CORP |
| 72083 | 02247790 | REPRONEX (menotropins 75 unit per vial powder for solution for injection with diluent solution) FERRING INC | REPRONEX (ménotropines 75 unité par fiole poudre pour solution injectable avec solution diluante) FERRING INC |
| 91730 | 02432897 | TELMISARTAN (telmisartan 40 mg oral tablet) PHARMASCIENCE INC | TELMISARTAN (telmisartan 40 mg comprimé oral) PHARMASCIENCE INC |
| 91731 | 02432900 | TELMISARTAN (telmisartan 80 mg oral tablet) PHARMASCIENCE INC | TELMISARTAN (telmisartan 80 mg comprimé oral) PHARMASCIENCE INC |
| 83559 | 02350386 | ULTRA STRENGTH NO ODOUR CREAM (trolamine salicylate 20 % cutaneous cream) CHURCH & DWIGHT CANADA CORP | ULTRA STRENGTH NO ODOUR CREAM (salicylate de trolamine 20 % crème cutanée) CHURCH & DWIGHT CANADA CORP |

## Blacklist (on GitHub)

Updates to the Blacklist to be applied for the DEC Release Candidate have been made. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 203213c9390a0139f4ce37a552814f58 | fentanyl (fentanyl citrate) 1000 mcg per 20 mL solution for injection | 98604 | 02496178 | FENTANYL INJECTION BP (fentanyl (fentanyl citrate) 1000 mcg per 20 mL solution for injection) STERIMAX INC | ADD |
| 047391f67b8ded96c0f14dda4a4f1b66 | fentanyl (fentanyl citrate) 250 mcg per 5 mL solution for injection | 98603 | 02496151 | FENTANYL INJECTION BP (fentanyl (fentanyl citrate) 250 mcg per 5 mL solution for injection) STERIMAX INC | ADD |
| 66b42a234df9ae8ff2375b5a50cbc3c0 | fentanyl (fentanyl citrate) 2500 mcg per 50 mL solution for injection | 98605 | 02496186 | FENTANYL INJECTION BP (fentanyl (fentanyl citrate) 2500 mcg per 50 mL solution for injection) STERIMAX INC | ADD |
|  |  | 86792 | 02382059 | ALLERJECT (epinephrine 0.15 mg per 0.15 mL solution for injection syringe) KALEO INC | REMOVE |
|  |  | 86793 | 02382067 | ALLERJECT (epinephrine 0.3 mg per 0.3 mL solution for injection syringe) KALEO INC | REMOVE |
| 3babf50ba3a4ef4533b3daeb6a1068a2 | sapropterin dihydrochloride 100 mg per sachet powder for oral solution | 97268 | 2482207 | KUVAN (sapropterin dihydrochloride 100 mg per sachet powder for oral solution) BIOMARIN INTERNATIONAL LIMITED | REMOVE |
| 173967ce8880d37329a5a994625bc320 | sapropterin dihydrochloride 500 mg per sachet powder for oral solution | 97269 | 2482215 | KUVAN (sapropterin dihydrochloride 500 mg per sachet powder for oral solution) BIOMARIN INTERNATIONAL LIMITED | REMOVE |

## NTP-Device File

The ntp-device file needs a correction to the last entry, code 600007. Status should be Active and effective date moved to the column on the right.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| device\_ntp\_code | device\_ntp\_formal\_name | device\_ntp\_en\_description | device\_ntp\_fr\_description | device\_ntp\_status | device\_ntp\_status\_effective\_time |
| 600001 | lancets | NA | lancettes | Active | 20170525 |
| 600002 | glucose meter | NA | glucomètre | Active | 20170525 |
| 600003 | glucose strips | NA | bandelettes de test glycémie | Active | 20170525 |
| 600004 | valved holding chamber with infant mask | NA | chambre de retenue valvée avec masque pour nourrisson | Active | 20200501 |
| 600005 | valved holding chamber with child mask | NA | chambre de retenue valvée avec masque pour enfant | Active | 20200501 |
| 600006 | valved holding chamber with adult mask | NA | chambre de retenue valvée avec masque pour adulte | Active | 20200501 |
| 600007 | valved holding chamber with mouthpiece | NA | chambre de retenue valvée avec embout buccal | 20200501 |  |